Monatin natural high-intensity sweetener from south african indigenous plant

Overview

Monatin is a naturally occurring high-intensity sweetener isolated from the root bark of Sclerochiton ilicifolius, a spiny-leafed hardwood shrub native to the rocky hills of the Limpopo Province in South Africa. The compound, chemically known as (Indol-3-yl)-2-amino-4-carboxy-4-hydroxypentanoic acid, offers sweetness intensity far exceeding that of conventional sugar. The 2S,4S isomer isolated from the natural plant is reported to be 1,200 to 1,400 times sweeter than sucrose, while the synthetic 2R,4R isomer achieves up to 2,700 times the sweetness of a 5% sucrose solution. Monatin is compatible with other sweeteners and forms acceptable blends, for example with aspartame, making it a versatile ingredient for food and beverage formulation.

Technical specifications

• Source: Naturally isolated from the root bark of the indigenous South African shrub Sclerochiton ilicifolius.
• Sweetness profile: 1,200 to 1,400 times sweeter than sucrose for the natural 2S,4S isomer; up to 2,700 times sweeter for the synthetic 2R,4R isomer.
• Blending compatibility: Forms acceptable sweetener blends with other high-intensity sweeteners such as aspartame.
• Production pathway: Biotechnology-based synthetic production methods have been developed and explored.
• Safety status: Extensive in vivo toxicology studies for the 2R,4R isomer have been completed, supporting progression toward commercialization.
• Prior development history: The technology has previously been licensed to multinational companies, with accumulated development expertise in isolation, characterization, and biotechnological synthesis.

Technology readiness level

Monatin has undergone prior development including isolation from the natural plant, biotechnological synthetic production, and extensive in vivo toxicology studies for the 2R,4R isomer. The technology has previously been licensed to multinational companies, though full commercialization was not achieved. Remaining steps toward market readiness include proposed commercial manufacturing scale-up and completion of safety studies in humans.